A Study of PVX-410 a Cancer Vaccine and Citarinostat +/- Lenalidomide for Smoldering MM

Study Overview

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma.

The following intervention will be involved in this study:

  • Lenalidomide
  • Citarinostat (CC-96241)
  • PVX-410

Study Description

A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma

  • ClinicalTrials.gov Identifier: NCT02886065
  • Protocol Number: 16-237
  • Principal Investigator: David Avigan

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000